Regeneron Pharmaceuticals Statistics
Total Valuation
REGN has a market cap or net worth of $61.23 billion. The enterprise value is $45.41 billion.
| Market Cap | 61.23B |
| Enterprise Value | 45.41B |
Important Dates
The last earnings date was Wednesday, April 29, 2026, before market open.
| Earnings Date | Apr 29, 2026 |
| Ex-Dividend Date | May 20, 2026 |
Share Statistics
REGN has 101.74 million shares outstanding. The number of shares has decreased by -5.61% in one year.
| Current Share Class | 99.92M |
| Shares Outstanding | 101.74M |
| Shares Change (YoY) | -5.61% |
| Shares Change (QoQ) | +0.19% |
| Owned by Insiders (%) | 3.83% |
| Owned by Institutions (%) | 89.72% |
| Float | 97.67M |
Valuation Ratios
The trailing PE ratio is 14.97 and the forward PE ratio is 12.68. REGN's PEG ratio is 1.17.
| PE Ratio | 14.97 |
| Forward PE | 12.68 |
| PS Ratio | 4.11 |
| Forward PS | 3.63 |
| PB Ratio | 1.99 |
| P/TBV Ratio | 2.03 |
| P/FCF Ratio | 14.89 |
| P/OCF Ratio | 12.22 |
| PEG Ratio | 1.17 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.36, with an EV/FCF ratio of 11.04.
| EV / Earnings | 10.27 |
| EV / Sales | 3.04 |
| EV / EBITDA | 10.36 |
| EV / EBIT | 11.82 |
| EV / FCF | 11.04 |
Financial Position
The company has a current ratio of 3.57, with a Debt / Equity ratio of 0.09.
| Current Ratio | 3.57 |
| Quick Ratio | 2.84 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | 0.61 |
| Debt / FCF | 0.66 |
| Interest Coverage | 80.06 |
Financial Efficiency
Return on equity (ROE) is 14.55% and return on invested capital (ROIC) is 12.93%.
| Return on Equity (ROE) | 14.55% |
| Return on Assets (ROA) | 6.13% |
| Return on Invested Capital (ROIC) | 12.93% |
| Return on Capital Employed (ROCE) | 10.75% |
| Weighted Average Cost of Capital (WACC) | 5.70% |
| Revenue Per Employee | $968,177 |
| Profits Per Employee | $287,047 |
| Employee Count | 15,410 |
| Asset Turnover | 0.38 |
| Inventory Turnover | 2.66 |
Taxes
In the past 12 months, REGN has paid $733.50 million in taxes.
| Income Tax | 733.50M |
| Effective Tax Rate | 14.22% |
Stock Price Statistics
The stock price has increased by +22.82% in the last 52 weeks. The beta is 0.30, so REGN's price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | +22.82% |
| 50-Day Moving Average | 716.64 |
| 200-Day Moving Average | 694.93 |
| Relative Strength Index (RSI) | 24.95 |
| Average Volume (20 Days) | 1,113,692 |
Short Selling Information
The latest short interest is 2.78 million, so 2.73% of the outstanding shares have been sold short.
| Short Interest | 2.78M |
| Short Previous Month | 3.27M |
| Short % of Shares Out | 2.73% |
| Short % of Float | 2.85% |
| Short Ratio (days to cover) | 3.55 |
Income Statement
In the last 12 months, REGN had revenue of $14.92 billion and earned $4.42 billion in profits. Earnings per share was $41.06.
| Revenue | 14.92B |
| Gross Profit | 6.55B |
| Operating Income | 3.84B |
| Pretax Income | 5.16B |
| Net Income | 4.42B |
| EBITDA | 4.38B |
| EBIT | 3.84B |
| Earnings Per Share (EPS) | $41.06 |
Balance Sheet
The company has $8.75 billion in cash and $2.71 billion in debt, with a net cash position of $15.83 billion or $155.63 per share.
| Cash & Cash Equivalents | 8.75B |
| Total Debt | 2.71B |
| Net Cash | 15.83B |
| Net Cash Per Share | $155.63 |
| Equity (Book Value) | 31.42B |
| Book Value Per Share | 308.32 |
| Working Capital | 13.10B |
Cash Flow
In the last 12 months, operating cash flow was $5.01 billion and capital expenditures -$899.70 million, giving a free cash flow of $4.11 billion.
| Operating Cash Flow | 5.01B |
| Capital Expenditures | -899.70M |
| Depreciation & Amortization | 540.00M |
| Net Borrowing | n/a |
| Free Cash Flow | 4.11B |
| FCF Per Share | $40.43 |
Margins
Gross margin is 43.89%, with operating and profit margins of 25.76% and 29.65%.
| Gross Margin | 43.89% |
| Operating Margin | 25.76% |
| Pretax Margin | 34.56% |
| Profit Margin | 29.65% |
| EBITDA Margin | 29.38% |
| EBIT Margin | 25.76% |
| FCF Margin | 27.57% |
Dividends & Yields
This stock pays an annual dividend of $3.76, which amounts to a dividend yield of 0.63%.
| Dividend Per Share | $3.76 |
| Dividend Yield | 0.63% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 8.86% |
| Buyback Yield | 5.61% |
| Shareholder Yield | 6.23% |
| Earnings Yield | 7.22% |
| FCF Yield | 6.72% |
Analyst Forecast
The average price target for REGN is $833.31, which is 38.47% higher than the current price. The consensus rating is "Buy".
| Price Target | $833.31 |
| Price Target Difference | 38.47% |
| Analyst Consensus | Buy |
| Analyst Count | 29 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
REGN has an Altman Z-Score of 6.53 and a Piotroski F-Score of 4.
| Altman Z-Score | 6.53 |
| Piotroski F-Score | 4 |